Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 by Driouich, J-S, Cochin, M, Touret, F, Petit, P-R, Gilles, M, Moureau, G, Barthélémy, K, Laprie, C, Wattanakul, T, Chotsiri, P, Hoglund, RM, Tarning, J, Fraisse, L, Sjö, P, Mowbray, CE, Escudié, F, Scandale, I, Chatelain, E, de Lamballerie, X, Solas, C, Nougairède, A

“…Then, we demonstrated nitazoxanide activity in a reconstructed bronchial human airway epithelium model. …”

Cholangiocarcinoma complicating secondary sclerosing cholangitis from cryptosporidiosis in an adult patient with CD40 ligand deficiency: case report and review of the literature. by Rahman, M, Chapel, H, Chapman, R, Collier, J

“…Despite both paromomycin and nitazoxanide, he developed sclerosing cholangitis secondary to cryptosporidial infection. …”

Dominant mutations in GRM1 cause spinocerebellar ataxia type 44 by Watson, L, Bamber, E, Schnekenberg, R, Williams, J, Bettencourt, C, Lickiss, J, Fawcett, K, Clokie, S, Wallis, Y, Clouston, P, Sims, D, Houlden, H, Becker, E, Németh, A

“…Crucially, the gain-of-function mutations could be pharmacologically modulated <i>in vitro</i> using an existing FDA-approved drug, Nitazoxanide, suggesting a possible avenue for treatment, which is currently unavailable for ataxias.…”